深圳肺癌患者用港澳良药，医保报销后惠民保又赔付7.2万元

Group 1 - The core viewpoint of the articles highlights the benefits of the "Shenzhen Huimin Insurance" program, which allows residents to access advanced cancer treatment drugs from Hong Kong and Macau without the need for cross-border travel, significantly reducing their financial burden [1][2] - The program covers specific cancer treatment drugs, such as "Injection Rubrictin," which has been utilized by patients like Mr. Li and Ms. Zhou, leading to substantial reimbursements after medical expenses [1] - The total medical expenses incurred by Mr. Li amounted to 255,800 yuan, with the insurance covering 72,000 yuan after deducting the deductible, while Ms. Zhou's expenses were 129,500 yuan, with the insurance covering 18,600 yuan [1] Group 2 - The "Shenzhen Huimin Insurance" program for 2025 will see improvements, including a reduction in the deductible from 35,000 yuan to 31,000 yuan, and a further reduction to 30,000 yuan for those who have been insured for over two years, thus lowering the claims threshold [2] - The coverage will expand to include 17 types of medical products from Hong Kong and Macau, with an annual maximum reimbursement limit of 500,000 yuan, enhancing access to quality medical resources for residents [2] - The enrollment deadline for the 2025 "Shenzhen Huimin Insurance" program is set for June 30, and it is open to individuals who are normally enrolled and pay Shenzhen medical insurance, as well as Shenzhen residents with medical insurance from other locations [2]